Mexico Antimicrobial Susceptibility Testing Market (2024-2029)
The Mexico Antimicrobial Susceptibility Testing Market was valued at $120.1 Million in 2024 and projected to reach to $152.6 Million by 2029, representing a compound annual growth rate of 4.9%. Mexico's antimicrobial susceptibility testing market is positioned for steady growth as healthcare providers prioritize diagnostic accuracy to combat rising antimicrobial resistance.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Mexico Antimicrobial Susceptibility Testing Market Trends and Insights
- Mexico's healthcare infrastructure is increasingly adopting advanced diagnostic technologies to combat rising antimicrobial resistance, a critical public health challenge in the region.
- The market growth in Mexico is driven by expanding laboratory capabilities, heightened awareness of antibiotic stewardship programs, and growing demand for rapid and accurate pathogen identification in clinical settings. Mexico's pharmaceutical and diagnostic sectors are investing in modernizing testing methodologies to meet international standards and regulatory requirements.
- The country's position as a major healthcare hub in Latin America positions Mexico as a key market for antimicrobial susceptibility testing solutions.
- Between 2024 and 2029, Mexico is expected to see increased adoption of automated and molecular-based testing platforms, supported by government initiatives and private sector investments in diagnostic infrastructure..
Key Market Statistics
- CAGR (2024-2029) 4.9% CAGR
- Market Size, 2024 ~USD 120.1 Million
- Forecast, 2029 ~USD 152.6 Million
- Country Mexico
Mexico Antimicrobial Susceptibility Testing Market Overview
Market Valuation :
Mexico's antimicrobial susceptibility testing market reached USD 120.1 million in 2024, with projected growth to USD 152.6 million by 2029, representing a steady 4.9% CAGR.
Rising Antimicrobial Resistance :
Mexico faces escalating antimicrobial resistance challenges, driving healthcare institutions to adopt advanced diagnostic technologies for accurate pathogen identification and treatment guidance.
Healthcare Infrastructure Modernization :
Mexican hospitals and diagnostic laboratories are increasingly investing in automated and rapid susceptibility testing platforms to improve clinical outcomes and reduce treatment failures.
Regulatory and Clinical Demand :
Growing compliance requirements and clinical demand for precision diagnostics are accelerating adoption of standardized antimicrobial susceptibility testing methods across Mexico's healthcare system.
Mexico Antimicrobial Susceptibility Testing Market Dynamics
- The country's expanding middle class and increasing healthcare spending are driving investments in modern laboratory infrastructure and diagnostic capabilities.
- Public health initiatives addressing antibiotic stewardship are further propelling demand for reliable susceptibility testing solutions. The forecast period through 2029 will see accelerated adoption of automated testing platforms and molecular diagnostic technologies in major urban centers and regional hospitals.
- Government support for infectious disease management and international partnerships with diagnostic manufacturers will enhance market accessibility.
- Mexico's strategic position in Latin America also positions it as a hub for diagnostic innovation and technology adoption in the region..
Related Ecosystem
Healthcare It
- Computed Tomography (CT)
- Machine Learning
- Magnetic Resonance Imaging (MRI)
- Natural Language Processing (NLP)
- Predictive Analytics
- CERNER CORPORATION
- PHILIPS HEALTHCARE
- Oracle Corporation
- GE HealthCare Technologies Inc.
- Siemens healthineers
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- CONMED Corporation
Key Takeaways
- Mexico's antimicrobial susceptibility testing market is valued at USD 120.1 million in 2024 and will reach USD 152.6 million by 2029.
- Mexico is experiencing a 4.9% CAGR, driven by rising antimicrobial resistance and healthcare modernization initiatives.
- Mexico's diagnostic laboratories are increasingly adopting automated and molecular-based testing platforms to improve clinical outcomes.
- Mexico's strategic position in Latin America makes it a critical market for antimicrobial susceptibility testing solution providers.
Antimicrobial Susceptibility Testing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | LAB INSTRUMENTS (Product) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 5% from 2024 to 2029 |
| Largest Segment | QUALITATIVE METHODS (Method) |
| Market Size Base Year (Billions) | ~USD 4.45 (2024) |
| Revenue Forecast (Billions) | ~USD 5.68 (2029) |
| Segments Covered | Product, Type, Method, Application, End User |
Mexico Antimicrobial Susceptibility Testing Market Report Segmentation
5 segment dimensions are covered across the global market.
By Product
- Consumables
- Lab Disposables
- Lab Instruments
By Type
- Agar Dilution
- Antibacterial Susceptibility Testing
- Antifungal Susceptibility Testing
- Antiparasitic Susceptibility Testing
- Antiviral Susceptibility Testing
- Automated Ast
- Automated Laboratory Instruments
- Broth Macrodilution
- Culture & Growth Media
- Culture And Growth Media
- Disk Diffusion
- Etest Method
- Genotypic Method
- Mic Strips
- Molecular Diagnostics Systems
- Susceptibility Plates
- Susceptibility Testing Disks
By Method
- Qualitative Methods
- Quantitative Methods
By Application
- Clinical Diagnostics
- Drug Discovery & Development
- Epidemiology
- Other Applications
By End User
- Academic & Research Institutes
- Cros
- Hospitals & Diagnostic Centers
- Pharmaceutical & Biotechnology Companies
Target Audience
- Diagnostic Equipment Manufacturers : Manufacturers need Mexico-specific market data to develop localized product strategies, identify distribution channels, and understand adoption barriers in automated and rapid testing platforms.
- Healthcare System Administrators : Hospital and laboratory directors require market insights to justify capital investments in AST infrastructure, benchmark against regional standards, and optimize diagnostic capabilities.
- In Vitro Diagnostics (IVD) Companies : IVD firms need detailed Mexico market analysis to assess commercial viability, competitive positioning, and growth potential for susceptibility testing reagents and consumables.
- Healthcare Consultants & Advisors : Consultants advising healthcare organizations or investors require comprehensive Mexico market data to support strategic recommendations and due diligence for market entry or expansion.
- Government & Public Health Agencies : Mexican health authorities and international health organizations need market intelligence to inform antibiotic stewardship programs, procurement decisions, and infectious disease management policies.
Reasons to Buy this Report
- Market Size & Growth Projections : Access precise valuation data for Mexico's AST market (USD 120.1M in 2024) with detailed 5-year forecasts to support investment decisions and business planning in this growing segment.
- Competitive Landscape Analysis : Understand key players, market consolidation trends, and competitive positioning specific to Mexico's healthcare diagnostic sector to identify partnership and expansion opportunities.
- Regulatory & Reimbursement Insights : Gain detailed knowledge of Mexico's healthcare regulations, reimbursement policies, and compliance requirements affecting AST adoption and market entry strategies.
- End-User Demand Drivers : Identify specific drivers of antimicrobial resistance in Mexico and understand hospital, laboratory, and clinical demand patterns to tailor product offerings and marketing strategies.
- Regional Market Segmentation : Access granular data on Mexico's geographic distribution, urban vs. rural adoption rates, and institutional capacity to prioritize market penetration and resource allocation.
Frequently asked questions
What is the current size of Mexico's antimicrobial susceptibility testing market?
Mexico's antimicrobial susceptibility testing market was valued at USD 120.1 million in 2024.
What is the projected market size for Mexico by 2029?
Mexico's antimicrobial susceptibility testing market is projected to reach USD 152.6 million by 2029.
What is the growth rate of Mexico's antimicrobial susceptibility testing market?
Mexico's antimicrobial susceptibility testing market is growing at a compound annual growth rate of 4.9% from 2024 to 2029.
What factors are driving growth in Mexico's antimicrobial susceptibility testing market?
Growth in Mexico is driven by rising antimicrobial resistance, expanding laboratory infrastructure, antibiotic stewardship programs, and adoption of advanced diagnostic technologies.
Which testing technologies are gaining adoption in Mexico?
Mexico is seeing increased adoption of automated and molecular-based antimicrobial susceptibility testing platforms in clinical and diagnostic laboratories.
RESEARCH METHODOLOGY
In that respect, the research has heavily employed both primary and secondary sources in order to comprehensively study the forces influential in the industry. This methodology comprised market segmentation analysis, industry trends, major players, competitive landscape, key market dynamics, and strategies of key companies.
Secondary Research
The secondary research involves D&B Hoovers, Bloomberg Businessweek, Factiva, white papers, annual reports, company filings, investor presentations, and SEC filings for conducting secondary research in developing a database on major industry participants. Key data with regard to leading players, market segmentation, at a various level, industry trends by segments, significant mergers and acquisitions, and the impact of trends and technological perspectives related to the antimicrobial susceptibility testing market.
Primary Research
Primary research in the report included interviewing a cross-section, both from the demand and supply sides, to capture information qualitatively and quantitatively. Supply side: High-level executives' interviews, such as CEOs, VPs, marketing and sales directors, regional sales managers, and technology and innovation directors were contacted from leading companies and organizations in product therapy markets. On the demand side, research was carried out by discussing with professionals like clinicians, procurement managers, purchase managers, department heads, and experts from hospitals, diagnostic centers, pharmaceutical and biotechnological firms, and research and academic institutes. This was necessary to gain a proper view of the market segmentation, significant players in the market, and key trends and dynamics related to the growth of the market.
A breakdown of the primary respondents is provided below:
*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 1 billion, Tier 2 = < USD 500 million, and Tier 3 = < USD 100 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
This research examines the Antimicrobial Susceptibility testing market and revenue share among the market leaders. It made use of a combination of primary and secondary research methods to do so. Primary research involved in-depth interviews with CEOs, directors, and senior marketing executives. Secondary research formed annual and financial reports by major industry players. The market value was determined while following a segment-based strategy, and it used revenue details of leading solution providers for differentiating between sources and services.
Covered segments:
Identify the major companies involved in the world Antimicrobial Susceptibility testing market and document their annual revenues or revenues from their particular product category/business division.
The revenue mapping of these leading competitors, based on 2024 data, captures a good share of the market and is thus extrapolated to estimate the total global value of the Antimicrobial Susceptibility testing market:
Data Triangulation
Based on the methodology, categorical and sub-categories segmentation of the global antimicrobial susceptibility testing market was performed. Further, data triangulation and the segmentation process were undertaken to arrive at an accurate data of different segments for the market. Various analyses involved factors and trends of the demand and supply sides. The integration of detailed top-down and bottom-up approaches offered a holistic overview of the antimicrobial susceptibility testing market
Market Definition
The Antimicrobial Susceptibility Testing market involves the diagnosis and determination of effectiveness against pathogens such as bacteria, fungi, and viruses using antimicrobial agents. It consists of several technologies and methodologies employed for the diagnosis of the susceptibility of microorganisms to a variety of antimicrobial agents through automated systems, molecular diagnostics, and traditional culture-based methods. The main aim of AST is to be able to choose appropriate therapy, enhance patient outcomes, and take against the threat of emerging antimicrobial resistance. The market includes products and services used by clinical laboratories, hospitals, research institutions, and other healthcare facilities.
Stakeholders
- Healthcare institutions (hospitals and clinics)
- Healthcare institutions (hospitals and diagnostic centers)
- Research institutions
- Clinical research organizations
- Academic medical centers and universities
- Reference laboratories
- Accountable Care Organizations (ACOs)
- Research and consulting firms
- Contract research organizations (CROs) and contract manufacturing organizations (CMOs)
- Academic medical centers and universities
- Market research and consulting firms
- Group Purchasing Organizations (GPOs)
- Medical Research Laboratories
- Academic Medical Centers and Universities
Report Objectives
- Define, describe, and project the antimicrobial susceptibility testing (AST) market across various dimensions, including product, type, methods, applications, end users, and regional areas.
- Explore opportunities for stakeholders and provide a detailed analysis of the competitive landscape, highlighting the key players in the market.
- Offer comprehensive insights into the principal factors influencing market growth.
- Analyze micro markets by evaluating individual growth trends, potential, and their contributions to the overall market.
- Monitor and review competitive developments such as new product launches, approvals, agreements, partnerships, expansions, acquisitions, and collaborations in the AST sector.
Get the Full Antimicrobial Susceptibility Testing Market Report
Full forecast, segment splits, and company analysis for all Antimicrobial Susceptibility Testing Market.
- Canada Antimicrobial Susceptibility Testing Market
- US Antimicrobial Susceptibility Testing Market
- Germany Antimicrobial Susceptibility Testing Market
- France Antimicrobial Susceptibility Testing Market
- UK Antimicrobial Susceptibility Testing Market
- Italy Antimicrobial Susceptibility Testing Market
- Spain Antimicrobial Susceptibility Testing Market
- Japan Antimicrobial Susceptibility Testing Market
- China Antimicrobial Susceptibility Testing Market
- India Antimicrobial Susceptibility Testing Market
- Australia Antimicrobial Susceptibility Testing Market
- South Korea Antimicrobial Susceptibility Testing Market
- Brazil Antimicrobial Susceptibility Testing Market
- Rest Of Europe Antimicrobial Susceptibility Testing Market
- Rest Of Asia Pacific Antimicrobial Susceptibility Testing Market
- Rest Of Latin America Antimicrobial Susceptibility Testing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
